Use this url to cite publication: https://hdl.handle.net/20.500.12512/80669
Options
Posternotomy mediastinitis due to Staphyloccocus aureus: comparison of clinical and pharmacoeconomical aspects / E. Kadusevicius, D. Zaliaduonyte, R. Benetis, A. Vitkauskiene, R. Levuliene
Type of publication
Tezės kitoje duomenų bazėje / Theses in other database (T1c)
Author(s)
Title
Posternotomy mediastinitis due to Staphyloccocus aureus: comparison of clinical and pharmacoeconomical aspects / E. Kadusevicius, D. Zaliaduonyte, R. Benetis, A. Vitkauskiene, R. Levuliene
Date Issued
2004
Extent
p. 115, abstract no. P 20.15.
Is part of
Fundamental & clinical pharmacology : abstracts of the 4th congress of the Federation of the European Pharmacological Societies (EPHAR), 14-17 July 2004 and of the Serotonin Satellite meeting, 17-19 July 2004, Porto, Portugal. Porto : Blackwell publishing., 2004, vol. 18, suppl. 1, July.
Version
Originalus / Original
Field of Science
Abstract
Aims To evaluate clinical and pharmacoeconomical outcomes of posternotomy mediastinitis (PSM) caused by methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA, respectively). Methods We reviewed hospital records of 61 pts. with S. aureus PSM who were treated from 1999 to 2002 in Kaunas University Hospital. Staphylococcus aureus was the infectious agent identified in wound secretion or in the mediastinum, or both. PSM was caused by MRSA in 12 pts and by MSSA in 49. Results Duration in-hospital stays for pts. with MRSA mediastinitis 63 days (63.33 ± 5.8) vs. 43 days (43.88 ± 4.18) for pts. with MSSA mediastinitis (P ¼ 0.0169). In-hospital mortality rate in MRSA mediastinitis group was significantly higher 33% vs. 4% of MSSA group respectively [relative risk (RR), 8.17; 95% confidence interval (CI), (1.89–34.57). Number needed to treat (NNT) ¼ )3.42 95% CI] ()12.37 to)1.74). Multivariate analysis using of the stepwise logistic regression method showed a relationship between mortality and the following variables: the MRSA infection itself (OR 9.152), and the duration of stay in intensive care unit (OR 1.085). 18-day treatment with vancomycin and fucid acid or rifampicin was more effective than 9-day treatment with vancomycin alone. Relative risk reduction 0.65; CI (0.56–0.94) of PSM-related death and treatment failure). Direct costs for antibiotic treatment for one patient in MRSA group was 880.85 ± 158.86euro; 95%CI (534.72–1226.99) vs. 249.63euro; 95%CI (123.52–375.75), P < 0.001. Incremental cost per one death avoided for antibiotic treatment (ICER) 2176.62euro. Conclusions MRSA infection causes worse outcomes and its treatment is more expensive than treatment of MSSA infection.
Is Referenced by
Type of document
type::text::conference output::conference proceedings::conference paper
ISSN (of the container)
0767-3981
Other Identifier(s)
(LSMU ALMA)990000665180107106
Coverage Spatial
Portugalija / Portugal (PT)
Language
Anglų / English (en)
Journal | IF | AIF | AIF (min) | AIF (max) | Cat | AV | Year | Quartile |
---|---|---|---|---|---|---|---|---|
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 1.711 | 2.526 | 2.526 | 2.526 | 1 | 0.677 | 2004 | Q3 |
Journal | IF | AIF | AIF (min) | AIF (max) | Cat | AV | Year | Quartile |
---|---|---|---|---|---|---|---|---|
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 1.711 | 2.526 | 2.526 | 2.526 | 1 | 0.677 | 2004 | Q3 |